Mifeprex (mifepristone)

P3, N=615, Active, not recruiting, Leiden University Medical Center | Recruiting --> Active, not recruiting | N=1186 --> 615 | Trial completion date: Apr 2030 --> Jan 2028 | Trial primary completion date: Apr 2029 --> Jun 2027

To explore P4-induced metabolic changes before and after the onset of HGSC, we analyzed serum samples from DKO mice treated with P4 or mifepristone, an inhibitor of P4 signaling, at premalignant and early tumor stages. Conversely, at this same stage, the targeted dataset showed notable increases in estrogens and glucocorticoids, while higher corticosterone levels were detected as HGSC began to develop. Overall, this study highlights the disruption of specific metabolites, phospholipid classes, and steroid hormones, in relation to HGSC tumor development under P4 treatment, suggesting their potential roles in OC development.

P=N/A, N=637, Completed, University of California, San Francisco

In vivo, ACC-bearing mice were treated with immune checkpoint inhibitors and mifepristone...Moreover, the percentage of macrophages detected by immunohistochemistry positively correlated with response to immunotherapy. Collectively, this study identifies a glucocorticoid-induced C1Q+ CD163 + macrophage phenotype that may contribute to T cell recruitment and enhance the efficacy of immunotherapy in ACC.

P=N/A, N=108, Completed, Affiliated Hospital of Nantong University; Affiliated Hospital of Nantong University | Not yet recruiting --> Completed

These findings demonstrate that M. longistyla extract possesses significant anti-hemorrhagic activity evidenced by reduced uterine bleeding, suppression of pro-inflammatory cytokine (TNF-α) and upregulation of VEGF. These effects suggest that the extract promotes endometrial repair and restoration of uterine homeostasis.

P3, N=1000, Not yet recruiting, University of Pennsylvania

Short-term mifepristone exposure does not produce molecular changes linked to endometrial carcinogenesis in BRCA1/2 pathogenic variant carriers. These findings provide important safety data for the future development of progesterone receptor modulators in cancer prevention. Long-term studies are needed to confirm these observations.

Mifepristone provided marked palliative benefit in this patient with nPR-negative, metastatic breast cancer, suggesting potential therapeutic value in similar cases. Confirmation of efficacy will require larger studies focused on tumors with absent or minimal nuclear progesterone receptor expression.

The study found that mifepristone treatment significantly reduced serum CA125 and PRL levels, and the 20 mg/kg/day dose was most effective in improving pregnancy outcomes. These findings suggest that mifepristone can reduce key biomarkers associated with uterine adenomyosis and improve fertility outcomes, offering a promising treatment option for women suffering from this condition.

Current treatment involves surgery, radiotherapy and chemotherapy (temozolomide), but survival rates remain low. Repurposing mifepristone (MF), a contraceptive drug, shows promise for GB treatment, warranting further study...The pilot trial demonstrated the pharmacological safety of using MF as an adjuvant in GB treatment. Patients treated with MF showed a significant increase in survival, with an 80% survival rate at 1 year compared to 0% in those who were treated with the standard treatment.

P2, N=24, Terminated, University of Chicago | N=74 --> 24 | Active, not recruiting --> Terminated; side effects (rash)